First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer

First-in-human SPECT/CT imaging of [²¹¹At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer

Eur J Nucl Med Mol Imaging. 2024 Dec 17. doi: 10.1007/s00259-024-07017-w. Online ahead of print.

Tadashi Watabe^{1

2}, Koji Hatano³, Sadahiro Naka⁴, Hidetaka Sasaki⁵, Takashi Kamiya⁵, Yoshifumi Shirakami⁶, Atsushi Toyoshima⁶, Jens Cardinale⁷, Frederik L Giesel^{6

7}, Kayako Isohashi⁸, Norio Nonomura³, Noriyuki Tomiyama^{8

6}

¹ Department of Radiology, Graduate School of Medicine, Osaka University, Suita, Japan. [email protected].
² Institute for Radiation Sciences, Osaka University, Suita, Japan. [email protected].
³ Department of Urology, Graduate School of Medicine, Osaka University, Suita, Japan.
⁴ Department of Pharmacy, Osaka University Hospital, Suita, Japan.
⁵ Department of Radiology, Osaka University Hospital, Suita, Japan.
⁶ Institute for Radiation Sciences, Osaka University, Suita, Japan.
⁷ Department of Nuclear Medicine, University Hospital Dusseldorf, Dusseldorf, Germany.
⁸ Department of Radiology, Graduate School of Medicine, Osaka University, Suita, Japan.

No abstract available